🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Cohort study finds metastases vary between histologic subtypes of mRCC, sites of metastatic involvement are associated with survival: ccRCC = ↑ lung, brain, adrenal, pancreas mets pRCC = ↑ lymph node mets chrRCC = ↑ liver mets Shaan Dudani Daniel Heng ja.ma/3c37XkC

Just out in JAMA Network Open: Sites of metastasis vary by histology in mRCC and are associated with OS. Thanks to all IMDC collaborators! Daniel Heng Toni Choueiri, MD Chun Loo Gan Guillermo de Velasco Camillo Porta Frede Donskov Sumanta K. Pal, MD, FASCO Ravindran Kanesvaran Neil Reaume MD jamanetwork.com/journals/jaman…

Daniel Heng Shaan Dudani OncoAlert OncologyEducation JAMA Network Open JAMA Oncology Congrats Shaan Dudani and Daniel Heng for this important work! Thanks for including us.

In this real-world study, Cabozantinib has activity across 1L-4L settings in #mRCC. Dose reduction for AEs was associated with better outcomes. Thanks to all IMDC collaborators! onlinelibrary.wiley.com/doi/full/10.10… Daniel Heng Toni Choueiri, MD Shaan Dudani Frede Donskov Ben Tran Sumanta K. Pal, MD, FASCO

RCC has diverse outcomes: proud to be part of work ASCO #GU21 from Toni Choueiri, MD Daniel Heng IMDC where we identify a very favorable prognostic group of patients meetinglibrary.asco.org/record/194630/… Ziad Bakouny, MD, MSc Shaan Dudani Neeraj Agarwal, MD, FASCO

4/ Looking at all patients with mRCC, incorporating the very favorable category into IMDC criteria, we can identify 4 distinct prognostic groups. Bryan Chan Jeff C Goh

Our IMDC analysis on the effectiveness of first-line ICI based therapy in advanced non-clear cell RCC! Daniel Heng Toni Choueiri, MD Sumanta K. Pal, MD, FASCO #GU21

Outcomes of 1st line combos in inter/poor-risk mRCC from IMDC Chun Loo Gan 🔶Higher ORR, lower PD with IO-VEGF/TKI 🔶Similar oncological outcomes! 🔶Higher irAEs with nivo-ipi but may predict better outcomes! OncoAlert #GU21

Now with Chun Loo Gan IMDC with real-word evidence showing equivalent OS and TTNT between IO-IO and IO-VEGF regimens in poor/interm. risk mRCC !! ASCO #GU21 ASCO Publications The ASCO Post Daniel Heng Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Ziad Bakouny, MD, MSc Laurence Albiges UroToday.com OncoAlert Dana-Farber

Thrilled to see our paper out in JAMA Oncology! Aly-Khan Lalani Toni Choueiri, MD Daniel Heng Shaan Dudani Frede Donskov IMDC The IO sequel to the original obesity paradox in mRCC! OncoAlert UroToday.com OncLive.com

Woderful work by Aly-Khan Lalani using the IMDC database w Daniel Heng Toni Choueiri, MD et al! The IMDC is a gift that keeps on giving ... valuable clinical insights. Ziad Bakouny, MD, MSc Shaan Dudani

As always, thanks to important contributions by international investigators, sites, and *most importantly* patients to team efforts like IMDC Sumanta K. Pal, MD, FASCO Ulka Vaishampayan Wanling @steinharterjack Justin Fleischer Pier Vitale Nuzzo Naveen Basappa, MD + more! 👏👏👏

For my colleagues in #GeriOnc, nice article led by Daniel V. Araujo & Shaan Dudani looking at age & outcome w ICIs in #kidneycancer. The IMDC strikes again (thx Daniel Heng Toni Choueiri, MD) suggesting no diff in OS based on age; RR diff in 1L intriguing?

Congratulations Jeffrey Graham!!

Just out in EJC: Outcomes of pts treated with 1L IO agents who were trial ineligible. Big thanks to all patients, Alberta Immunotherapy Database Daniel Meyers IgorStukalin, IMDC collaborators and my mentor Daniel Heng Toni Choueiri, MD Sumanta K. Pal, MD, FASCO OncoAlert sciencedirect.com/science/articl…

Alberta Immunotherapy Database-led study shows pts that are trial ineligible by common criteria have poorer associated outcomes to 1st line IO in #kidneycancer #lungcancer #melanoma so expectations need to be tempered. albertacancer #RWE IMDC Proud of Chun Loo Gan🇦🇺🇨🇦🇲🇾!

Using nomograms in the real world is tricky and hides clinical variation. We built an interactive viz for #kidneycancer outcomes, using IMDC Criteria with Daniel Heng @MontyPal Toni Choueiri, MD @gorejohn timelyportfolio Kevin Shee, MD, PhD imdconline.com/cloviz #digitalhealth #RStats

Phenomenal work from Anobel Odisho collaborating with IMDC Toni Choueiri, MD Daniel Heng @gorejohn - this will be a useful tool for so many!

JUST IN: Cytoreductive Nephrectomy for Metastatic RCC Treated with Immune Checkpoint Inhibitors or Targeted Therapy: The IMDC does it again ! #IMDC Daniel Heng with Talal El Zarif, MD Ziad Bakouny, MD, MSc Shaan Dudani et al in European Urology secure-web.cisco.com/1nOqqWr2rKW30O…

Post-call in the CCU, so late in sharing this but thrilled to see our work on upfront cytoreductive nephrectomy in metastatic RCC now published in European Urology Huge thanks to co-first author Talal El Zarif, MD and co-senior Wanling Daniel Heng Toni Choueiri, MD & IMDC (1/1)